Background: PCI of aorto-ostial lesion is known to be associated with reduced procedural success, increased complications and restenosis. This study aimed to evaluate the efficacy and safety of DES for the treatment of native coronary ostial lesions compared to the non-ostial lesions. Methods: A total 63 patients (pts) with 85 ostial lesions (Ostial group) and 214 pts with 313 non-ostial lesions (Non-ostial group) underwent standard PCI with DES. The in-hospital, 6-month clinical and angiographic outcomes in both groups were compared. Results: Baseline characteristics were similar between the two groups except ostial group received more Sirolimus-eluting stent (CypherTM) than Paclitaxel-eluting stent (TaxusTM) (64.1% vs. 35.9%, p=0.32). Among the ostial group, left main was 10.6% (9/85), LAD 42.4% (36/85), LCX 28.2% (24/85) and RCA 18.8% (16/85). DES diameter was similar but length was shorter in ostial group (24.1짹6.2 mm vs. 26.4짹5.4 mm, p=0.004). The ostial group had similar procedural and in-hospital complications. At 6 months, binary restenosis, restenosis % and major adverse cardiac events (MACE) including death, myocardial infarction and revascularization were similar between two groups (Table). Conclusions: Treatment of ostial lesion in pts undergoing PCI with DES is safe and feasible with low procedural and in-hospital complications. Six-month clinical and angiographic follow-up showed sustained benefit of DES on the ostial lesions without increasing any MI, TLR, TVR and MACE compared with the non-ostial lesion.